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Edited by Berend WieringaAbstract Transgenic (Tg) mice carrying four extra octapeptide
repeats (OR) in the bovine PrP gene (10OR instead of 6) have
been generated. In these mice, neuropathological changes were
observed depending upon the level of transgene expression. These
changes primarily involved a slowly advancing neurological dis-
order, characterized clinically by ataxia, and neuropathologi-
cally, by vacuolization in diﬀerent brain areas, gliosis, and loss
of cerebellar granule cells. Accumulation of insoluble bovine
10OR-PrP (bo10OR-PrP) was observed depending on the level
of expression but no infectivity was found associated with this
insoluble form. We also compared the behavior of bo6OR-PrP
and bo10OR-PrP Tg mouse lines in response to BSE infection.
BSE-inoculated bo10ORTg mice showed an altered course of
BSE infection, reﬂected by reduced incubation times when com-
pared to bo6ORTg mice expressing similar levels of the wild type
6OR-PrP. In BSE-inoculated mice, it was possible to detect
PrPres in 100% of the animals. While insoluble bo10OR-PrP
from non-inoculated bo10ORTg mice was non-infectious, brain
homogenates from BSE-inoculated bo10ORTg mice were highly
infectious in all the Tg mouse lines tested. This Tg mouse model
constitutes a new way of understanding the pathobiology of
bovine transmissible spongiform encephalopathy. Its potential
applications include the assessment of new therapies against
prion diseases.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Transmissible spongiform encephalopathies (TSEs), also
termed prion diseases, comprise a group of neurodegenerative
disorders in which spongiosis, astrocytosis, microglial activa-
tion and neuronal loss are common pathological events of
the central nervous system (CNS). Prion diseases of infectious
aetiology have been described in animals, i.e., BSE and Scrapie*Corresponding author. Fax: +34 91 620 22 47.
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doi:10.1016/j.febslet.2005.09.099[1–3] as well as in humans, i.e., kuru and vCJD [4,5]. Sponta-
neous and familial TSE aetiology have been only described in
humans including Creutzfeldt–Jakob disease (CJD) [6], Gerts-
mann–Stra¨ussler–Scheinker syndrome [7,8] and fatal familial
insomnia [9–13]. It is generally accepted that misfolding of
the cellular prion protein (PrPC) leads to the accumulation in
the brain of an insoluble, toxic PrP isoform (PrPSc). PrP is
the product of the Prnp gene constitutively expressed in the
brain as a cell-surface, GPI anchored, glycoprotein containing
a region of octapeptide repeats (OR) close to the N-terminus.
Point mutations and extra octapeptide insertions in the PrP
protein have been found in familial TSEs. Several lines of
transgenic (Tg) mice have been developed to model the patho-
physiology of these mutation-associated TSE disorders [14,15].
In these mice spontaneous neurological illness develops, resem-
bling common features of prion disorders. In addition, the
severity of the spontaneous prion disease is inﬂuenced by the
number of extra OR inserted [16].
A pathogenic insertion has never been described in cattle. Tg
mice expressing bovine PrP with one extra OR insertion (7OR-
PrP) show reduced incubation and survival times after BSE
prion inoculation compared to boTg mice with the wild type
(wt) 6OR-PrP [17], yet no neuropathological disorders have
been related to natural cases of cows with 7OR-PrP or ob-
served in Tg mice [18,19].
In this study, we show the generation of a Tg mouse carrying
a transgene encoding bovine PrP with four extra OR insertion
(10OR-PrP) as a model of ‘‘genetic’’ bovine encephalopathy. A
slowly progressive neurological disorder characterized by atax-
ia and neuropathological changes was observed when the level
of 10OR-PrP expression was high. A new insoluble and weakly
proteinase-K resistant bovine 10OR-PrP form was found but
no infectivity could be associated to it. Tg mice expressing
low levels of 10OR-PrP, did not show any neurological sign
but showed reduced incubation and survival times after BSE
prion inoculation compared to Tg mice expressing the wt
bovine 6OR-PrP. These results conﬁrm that human PrP-asso-
ciated insertional mutations confer identical neuropathological
phenotypes within the context of a bovine PrP. In addition,
these ﬁndings suggest a role for the OR gene region in
toxicitypathology and in eﬃciency of prion conversion and
propagation.ation of European Biochemical Societies.
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2.1. Plasmid constructs
The open reading (ORF) of the bovine PrP gene was isolated by
PCR ampliﬁcation from bovine DNA using primers that create a XhoI
restriction enzyme site adjacent to the translation start codon (5 0-
CCGCTCGAGGCCATCATGGTGAAAAGCCATATAG-3 0) and
to the stop site (5 0-CGGCTCGAGCTATCCTACTATGAG-3 0). The
5 0 primer also included Kozak sequences [20]. The PCR fragment
was subcloned into a T-tailed vector and the insert was sequenced, con-
ﬁrming six copies of the OR sequence and no changes in the inferred
amino acid sequence with respect to previously sequenced bovine
PrP genes (GenBank Accession No. AF455119). The four extra octare-
peats were introduced into the six octarepeat bovine PrP gene as
follows: 5 0-CATGGAGGTGGCTGGGGCCAGCCC-3 0 and 5 0-CAT-
GGGGCTGGCCCCAGCCACCTC-3 0 primers were used to obtain a
tandem of 4 artiﬁcial octarepeats containing ends compatible with the
NcoI restriction enzyme site. The PrP ORF was partially cut with NcoI
to avoid eliminating the constitutive OR, and the tandem of 4 artiﬁcial
octarepeats containing extremes compatible with NcoI was inserted
(supplemental ﬁgure 1). The six (6OR) and ten (10OR) octarepeat
PrP ORFs were excised from the T-tailed vector with the restriction en-
zyme XhoI and inserted into MoPrP Æ Xho [21], also digested with
XhoI. This vector contains the murine PrP promoter and exon 1, intron
1, exon 2 and 3 0 untranslated sequences.
2.2. Generation of Tg mice
MoPrP Æ Xho bovine transgene (6OR and 10OR) containing frag-
ments were excised from the plasmid vector with the restriction endonu-
clease NotI to give rise to a 12.1 kb DNA fragment that was
subsequently puriﬁed using sodium chloride gradients as previously
described [39]. Finally, the DNA for microinjection was resuspended
in TE (10 mM Tris, pH 7.4, 0.1 mM EDTA) at a ﬁnal concentration
of 2–6 lg/ml and used to microinject 350 or 257 pronuclear stage ova
for the 6OR or 10OR constructs, respectively. One-cell embryos were
obtained from superovulated B6CBAf1 females mated to 129/Ola males
carrying a null mutation in endogenous PrP [22] and were microin-
jected. Homozygous Tg lines were established in two steps. Founders
were backcrossed to homozygous null animals muPrP/ (Prnp/)
to obtain homozygosity for the null mutation. Interbreeding within
the same Tg line was performed to obtain homozygosity for the bovine
PrP constructs. Hybrids B6CBA · 129/Ola mice and Prnp/mice were
used as controls in all the infectivity studies.
2.3. Screening of founders
DNA was prepared from tail biopsies as previously described [23].
The MoPrP Æ Xho bovine transgenes were identiﬁed by a PCR assay
using speciﬁc primers for the mouse PrP exon 2 and the bovine PrP
open reading frame. The primers used were 5 0-CCAGCCTCCAC-
CACCATGTGGC-3 0 and 5 0-CATTCTGCCTTCCTAGTGGTACC-
3 0. The presence of PCR ampliﬁed products of 315 and 411 nucleotides
was indicative of MoPrP Æ Xho 6OR and 10OR bovine transgenes,
respectively. The absence of murine PrP ORFs in Tg mice was con-
ﬁrmed by PCR using the primers 5 0-ATGGCGAACCTTGGC-
TACTGGC-3 0 and 5 0-GATTATGGGTACCCCCTCCTTGG-3 0.
2.4. Source of BSE inoculum – Preparation of brain homogenates
A pool of BSE material (TSE/08/59) obtained from the brainstem of
49 BSE infected cattle and supplied by the Veterinary Laboratory
Agency (VLA) (New Haw, Addlestone, Surrey, UK) was used for most
of the experimental inoculations and was denoted BSE1. A diﬀerent
BSE inoculum (RQ 225:PG1199/00), BSE2, obtained from one BSE
infected brainstem supplied by the VLA was used for comparative
infection studies along with BSE1. The BSE2 inoculum contains 8- to
16-fold more PrPres than BSE1, as detected by immunoblot analysis
[18]. Pools of brain homogenates from a non-inoculated bo10ORTg
mouse line sacriﬁced 150 days after birth containing high amounts of
insoluble 10OR-PrP were used in infectivity experiments and denoted
bo10ORTg006. Finally, pools from a ﬁrst passage of BSE1 inoculum in
the mouse line bo10ORTg012 were used for some experiments and
referred to as bo10ORTgBSE1. The BSE2 inoculum also contains a
greater amount of PrPres than the bo10ORTgBSE1 inoculum, as
detected by immunoblot analysis (supplemental ﬁgure 2). In all the
experiments, phosphate buﬀered saline (PBS) was used as a negativeinoculation control and brain homogenates (10% wt/vol) were pre-
pared in sterile PBS lacking Ca2+ or Mg2+ by mechanical homogeniza-
tion (OMNI International, Warrenton, VA, USA). To minimize the
risk of bacterial infection, all inocula were preheated for 10 min at
70 C before being used to inoculate mice.
2.5. Infection experiments
Groups of 4–13 mice (six to seven weeks old, weighing approxi-
mately 20 g) were inoculated in the right parietal lobe using a 25 gauge
disposable hypodermic syringe. 20 ll of 10% brain homogenate were
delivered to each animal. To evaluate the clinical signs appearing after
inoculation, mice were observed daily and their neurological status was
assessed twice-weekly. The presence of two or three signs of neurolog-
ical dysfunction (using 10 diﬀerent diagnostic criteria) [24,25] was nec-
essary to score a mouse positive for prion disease. When progression of
the disease was evident, animals were culled for ethical reasons and
their brains harvested for analysis. These specimens were used to deter-
mine PrPres deposits in brain preparations by either Western blot or
immunohistochemistry (IHC) a for histopathology and IHC studies.
2.6. Histopathology and IHC
Brains were ﬁxed by immersion in 10% buﬀered formalin for 1 week
and then cut into four and placed in 98% formic acid for 1 h before
routine processing and paraﬃn wax embedding. 5 lm-thick sections
were cut and stained with hematoxylin and eosin (HE) or Nissls stain
for routine histopathological examination and for immunohistochem-
ical techniques. Sections were examined from: (a) the medulla oblon-
gata at the level of the obex and the pontine area; (b) the
cerebellum; (c) the diencephalon including thalamus; (d) the hippo-
campus and (e) the cerebral cortex. We assessed spongiform changes,
astrocytosis, eventual neuronal changes and PrP deposits at any level.
All histological changes were graded semi quantitatively on a 0–3 scale
basis.
The avidin–biotin–peroxidase complex technique was used for the
immunohistochemical study of PrPres and glial ﬁbrillary acid protein
(GFAP). After dewaxing and dehydration, endogenous peroxidase
was quenched by incubation with 3% hydrogen peroxide in methanol
for 30 min at room temperature. Samples for PrPres labeling were rehy-
drated, pretreated with 98% formic acid for 15 min at room tempera-
ture, 4 M guanidine isothiocyanate for 2 h at 4 C, and proteinase K
(Roche, Germany) treated (4 lg/ml in Tris–HCl, pH 7.8) for 15 min
at 37 C. Tissue sections were rinsed in phosphate buﬀered saline
(PBS, pH 7.4, 0.01 M) and blocked with 10% normal goat serum (Sig-
ma Chemical Co.) for 30 min at room temperature. Samples were incu-
bated overnight at 4 C with primary 6H4 monoclonal antibody (mAb)
(Prionics, Switzerland) or 2A11 mAb [26] diluted 1:400 in PBS. A sec-
ondary biotinylated goat anti-mouse Ig G (Dako, Glostrup, Denmark)
antibody diluted 1:20 in PBS and an avidin–peroxidase complex (Vec-
tor, Burlingame, UK) were used. Sections were developed using a 3,3 0-
diaminobenzidine tetrahydrochloride substrate (Sigma). The slides
were then counterstained with Mayers hematoxylin for 1 min, dehy-
drated and routinely assembled.
Samples for GFAP labeling were rehydrated without pretreatment
and blocked as described above. Sections were incubated overnight
at 4 C with the primary anti-bovine GFAP polyclonal antibody
(Dako) diluted 1:500 in PBS. Goat anti-rabbit Ig G (Vector) diluted
1:200 in PBS was used as the secondary antibody and the rest of the
technique was continued as described above. As negative controls, spe-
ciﬁc primary antibodies were replaced with PBS, and non-immune
mouse serum or non-immune rabbit serum were used in tissue sections.
2.7. Insolubility and PK resistance studies of PrPC and PrPres from non-
inoculated or BSE-inoculated bo6ORTg and bo10ORTg mouse lines
For the insolubility studies, brain homogenates from non-inoculated
bo6ORTg and bo10ORTg mouse lines were homogenized in 10%
Sarkosyl in PBS, pH 7.4 and the complete cocktail of protease inhib-
itors (Roche). 100 ll of the samples were pre-cleared by centrifugation
at 2000 · g. Soluble (S) and insoluble (P) fractions were obtained by
ultracentrifugation at 100000 · g for 1 h. Insoluble fractions were
washed exhaustively in 5% Sarkosyl in PBS, pH 7.4 and subjected to
a further ultracentrifugation step. For PK resistance studies, non-inoc-
ulated and BSE-inoculated brain homogenates from bo6ORTg110 [27]
or bo10ORTg012 mouse lines and from cattle were digested with 0,
7.5, 15, 30, 60, 125, 250, 500 and 1000 lg/ml of PK for 60 min at
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added to all the samples and each was boiled for 5 min before loading
onto a SDS/12% polyacrylamide gel. The Mab 2A11 was used at a 1/
1000 dilution for immunoblotting. Immunocomplexes were detected
using a horseradish peroxidase conjugated anti mouse IgG (Sigma
Chemical Co.) antibody. Immunoblots were developed according to
enhanced chemiluminescence protocols.2.8. Western blots
The analysis of PrPC expression in Tg mice was performed as fol-
lows. Brains from mice were homogenized in extraction buﬀer (0.5%
NP40, 1% sodium deoxycholate, 10 mM EDTA in PBS, pH 7.4) and
the complete cocktail of protease inhibitors (Roche) or in 10% Sarko-
syl in PBS and the complete cocktail of protease inhibitors (Roche).
Samples were pre-cleared by centrifugation at 2000 · g for 5 min and
either treated with 20 lg/ml of proteinase K (Roche) for 60 min at
37 C or left untreated. An equal volume of 2· SDS reducing sample
loading buﬀer was added to all samples and each one was boiled for
5 min before loading on a SDS/12% polyacrylamide gel. MAbs 6H4
and 2A11 were used at 1/5000 and 1/1500 dilutions, respectively, for
immunoblotting. Immunocomplexes were detected with horseradish
peroxidase conjugated anti mouse IgG. Immunoblots were developed
by enhanced chemiluminescence.2.9. Statistical analysis
The statistics SPSS 10.0 package was used to generate all the Kap-
lan–Meier curves and statistical data. Data were analyzed using the
Students t test for non-paired variants. Incubation times were ana-
lyzed after testing for normality (Kolmogorov–Smirnow test) and for
equal variance (Levene Median test) by one way ANOVA followed
by multiple pair wise comparison using Fishers LSD test. The level
of signiﬁcance was set at P < 0.05.Fig. 1. Expression of bovine 10OR-PrP proteins in heterozygous (mo+/
bo10ORTg mouse lines 006, 010, 012 and 029 using the monoclonal antibody
(A). Serial dilutions of heterozygous (mo+/ bo+/) bo10ORTg (006, 012 an
Western blotting using monoclonal antibody 2A11 (B). Bo, cow brain ext
kilodaltons.3. Results
3.1. Bo10ORPrPC expression in Tg mice
We obtained four diﬀerent lines (founders) carrying bovine
(bo) 10OR-PrPC (bo10ORPrPC). All these lines also bore wt
murine (mo) PrPC with 5 octarepeats (mo5ORPrPC). The
expression of PrPC in these lines carrying both murine 5OR-
PrPC and bovine 10OR-PrPC transgenes (PrP mo+/ bo+/)
was evaluated by subjecting brain homogenates to Western
blot analysis using the 2A11 mAb (Fig. 1A), which recognizes
both boPrPC and moPrPC (9). It was possible to distinguish
between wt murine (5OR) and bovine (10OR) PrP according
to their relative electrophoretic mobility. As shown in
Fig. 1A, the increased number of OR corresponds to an in-
creased relative molecular mass.
Bo10ORTg010 mice died in their fourth week of life and
failed to breed. The remaining Tg mouse lines (PrP mo+/
bo+/), bo10ORTg006, bo10ORTg012 and bo10ORTg029
were bred to homozygosity in a murine PrP null background
(PrP mo/). This was achieved by crossing the selected lines
with PrP null mice to obtain heterozygous transgene lines
(PrP mo/ bo+/). Then, by crossing heterozygous animals,
we obtained the transgene genotype (PrP mo/ bo+/+). The
absence of the murine PrP gene in these animals was conﬁrmed
by PCR using speciﬁc primers (data not shown). Next, we
established transgene expression levels in each mouse line by
serial dilution of brain homogenates and compared these to
PrPC levels in bovine brain homogenates. PrPC expressionbo+/) boTg mouse lines. Immunoblotting of brain extracts from
2A11. Equivalent amounts of total protein were loaded onto each lane
d 029 mouse lines) and bovine brain homogenates were analyzed by
ract; Mo, B6CBAx129/Ola brain extract. Relative molecular mass in
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bo10ORTg006, bo10ORTg012 and bo10ORTg029 were found
to be 4·, 0.5· and 0.25·, respectively (Fig. 1B). Further, all the
homozygous transgene lines tested showed double the PrP
expression levels detected in their heterozygous counterparts
(data not shown).
The behavior and phenotype of the homozygous bo10ORTg-
012 and bo10ORTg029 mouse lines showing 10OR-PrP expres-
sion levels of 1·, 0.5·, respectively, were identical to those
of normal mice. Mean survival times of bo10ORTg012
and bo10ORTg029 were 685 ± 42 (mean days ± S.E.M.)
and >600, respectively. However, the bo10ORTg010 and
bo10ORTg006 lines, with PrP expression levels of around
4–8· showed extensive neurological damage. Bo10ORTg010
mice died within the ﬁrst month of life presenting severe atax-
ia and bo10ORTg006 mice showed motor impairment with
ataxia mainly aﬀecting the hind limbs and also had breeding
diﬃculties. This line was unable to yield homozygous individ-
uals for the bovine 10OR-PrP transgene. The lifespan of this
Tg mouse line was only 180 ± 10 (mean days ± S.E.M.) and
the onset of clinical signs occurred on day 118 ± 6.Fig. 2. Histological changes in the cerebellum of bo10ORTg compared
to bo6ORTg mice. (A1) Low-power view of atrophy of the cerebellar
folia, showing white matter (WM) and cortex (Cx) (H/E, 4·). (A2)
Nissl staining reveals the intense loss of granular cells (G), with
preservation of Purkinje cells (P) (Nissl, 10·). (C1) Speciﬁc severe
degeneration of cerebellar granular cells is not associated with
conspicuous vacuolation (H/E, 10·). (C2) Immunostaining for GFAP
shows a band of astrocytosis deﬁning the granular cell layer (GFAP,
10·). (B1) Low-power view demonstrating the normal size of the
cerebellar layers (H/E, 10·). (B2) Nissl staining shows a normal
granular layer and Purkinje cells (Nissl, 20·). (D1) H&E staining
reveals a normal granular layer and Purkinje cells and lack of
vacuolation (H/E, 20·). (D2) Immunostaining for GFAP shows
several astrocytes mostly in the cerebellar white matter (GFAP, 10·).
Bo10ORTg and bo6ORTg mice were sacriﬁced a 180 after birth.3.2. Neuropathological alterations in bo10ORTg mouse lines
The bo10ORTg010 and bo10ORTg006 lines with PrP
expression levels of around 4–8· showing extensive neurolog-
ical damage were used to characterize the genetic/spontaneous
prion-related disease observed. Although for these two lines
the clinical signs were visually apparent and used for the diag-
nosis of the disease, the most important features were the his-
tological changes in the cerebellum, characterized by atrophy
of cerebellar folia with an intense loss of granular cells, but
with preservation of the Purkinje cells (Figs. 2A(1) and
A(2)). This speciﬁc severe degeneration of cerebellar granular
cells was not associated with conspicuous vacuolation
(Fig. 2C(1)). GFAP immunostaining detected a band of astro-
cytosis outlining the granular cell layer (Fig. 2C(2)). Other
morphological changes such as spongiosis associated with
the dentate gyrus were observed in the hippocampus but there
was no evidence of neuronal loss at this level. In this area, the
dentate gyrus, spongiosis was also related to several intraneu-
ronal vacuoles (Fig. 3).
The bo10ORTg006 mouse line showed a highly consistent
neuropathological phenotype, with intense loss of granular cell
layer neurons and relative preservation of Purkinje cells, but
no PrP deposits could be detected through IHC. Moreover,
Gallyas and tau immunostaining (data not shown) indicated
no neuroﬁbrillary pathology.
In order to establish the kinetics of neuropathological alter-
ations, as well as the earliest time point at which they can be
detected, we used bo10ORTg006, bo10ORTg012 and
bo10ORTg029 mouse lines expressing 4-, 1- and 0.5-fold
PrPC levels, respectively. Animals were grouped according
to pre-established culling times (60, 90, 120, 150, 180, 240,
300 and 400 days after birth). Mice were sacriﬁced at the
indicated time points independently of the onset of neurolog-
ical signs. As shown in Table 1, neuropathological alterations
were assessed at diﬀerent time points. Neurological diagnosis
was achieved using lesion proﬁles including alterations in the
cerebellum, brainstem, thalamus, striatum and hippocampus.
Animals carrying the PrP-10OR insert mutation from the
bo10ORTg006 mouse line mainly showed the lesion proﬁlescored as 3 (Table 1), and in most cases, pathological changes
were conﬁned to the cerebellum and the hippocampus.
Although clinical signs and neurological alterations deter-
mined by IHC were well correlated, at early times such as
60–90 days after birth, individual animals from the
bo10ORTg006 mouse line showed the ﬁrst histopathological
changes consistent with slight cerebellar and hippocampal
damage. At 120 days after birth, when clinical signs were evi-
dent, the cerebellar cortex showed a moderate to intense loss
of granule cells, with signs of karyorrhexis in several cases,
and preservation of Purkinje cells. GFAP staining demon-
strated a band of astrocytosis outlining the atrophic granular
layer. However, there were no spongiform changes observed
at this level. The hippocampal formation showed mild to se-
vere focal spongiosis involving the dentate gyrus, not associ-
ated with conspicuous neuronal loss or astrocytosis. No PrP
deposits in the brain tissue of any of the three groups of ani-
mals were observed using immunohistochemical stains.
Fig. 3. Morphological changes observed in the hippocampus of
bo10ORTg compared to bo6ORTg mice. (A1) Low-power image
shows focal spongiosis associated with the dentate gyrus (DG) (Nissl,
4·). (A2) Intermediate-power image shows spongiosis with no evidence
of neuronal loss at this level (Nissl, 10·). (C1) High-power view of a
similar area shows spongiosis along with several hypertrophic astro-
cytes (H/E, 20·). (C2) A similar area of the dentate gyrus shows
spongiosis and several intraneuronal vacuoles (V) (Nissl, 20·). (B1)
Normal structure of the dentate gyrus (Nissl, 10·). (B2) Nissl staining
shows no evidence of neuronal loss or vacuolation (Nissl, 20·). (D1)
H&E staining shows a normal dentate gyrus, absence of vacuolation
and no hypertrophic astrocytes (H/E, 20·). (D2) Immunostaining for
GFAP shows normal astrocytes in the dentate gyrus and other layers
of the hippocampus (GFAP, 10·). Bo10ORTg and bo6ORTg mice
were sacriﬁced a 180 after birth.
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012 and bo10ORTg029 mouse lines, however, failed to show
any histopathological signs at least up to 400 days after birth
(Table 1). These observations indicate that the rate at which
the illness progresses is strongly related to the expression level
of bo10OR-PrPC.
3.3. Insolubility and proteinase-K sensitivity studies on
10OR-PrPC
Since 10OR-PrPC contents in the brain of Tg mice produced
neurological alterations even at levels where wt 6OR-PrPC
does not cause these signs [27], we then tried to establish
whether the insertion of four extra octarepeats would modify
the biochemical properties of the bo10OR-PrP protein, in rela-
tion to the wt bo6OR-PrP protein. To this end, brain homog-
enates from bo6ORTg and bo10ORTg (line 006) mouse lines
were solubilized in extraction buﬀer and ultracentrifuged at
100000 · g for 1 h as described in Section 2. Subsequent Wes-tern blotting of the soluble and insoluble proteins indicated
diﬀerential biochemical behavior of the bo6OR-PrP and
bo10OR-PrP proteins (Fig. 4A). While the addition of one ex-
tra octarepeat did not alter the biochemical properties of PrP
[17], the presence of four extra octarepeats rendered a more
insoluble protein. This insolubility was detected early on (30
days after birth) in the lifespan of the mouse, indicating that
quantiﬁcation of the 10OR-PrP could reﬂect a cumulative
eﬀect (data not shown).
To evaluate the protease sensitivity of the mutant 10OR-
PrPC compared to wt 6OR-PrPC, brain homogenates were
treated with diﬀerent concentrations of proteinase-K (PK)
(see Section 2). While all bovine 6OR-PrPC was completely di-
gested at PK concentrations higher than 7.5 lg/ml, bovine
10OR-PrPC was slightly more resistant to lower concentrations
of PK (Fig. 4B). However, the degree of resistance was much
lower than the one shown by the pathogenic isoform 10OR-
PrPSc obtained after BSE inoculation (Fig. 4B).
3.4. Brain homogenates from spontaneously ill bo10ORTg
mice do not contain detectable infectivity
To test the infectivity in the brain of bo10OR-PrP Tg mice,
brain homogenates were prepared from bo10ORTg006 mice
sacriﬁced after spontaneous development of clinical signs.
These homogenates were intracerebrally inoculated in ﬁve dif-
ferent Tg mouse lines: three lines expressing diﬀerent levels of
wt 6OR-PrPC as well as bo10ORTg012 and bo10ORTg029
mouse lines. The PrP expressed by the bo10ORTg lines 012
and 029 should be a particularly eﬃcient substrate for assess-
ing infectivity, because it has the same amino acid sequence
as the PrP present in the inocula. The inoculum used showed
a high amount of insoluble bo10OR-PrPC (supplemental ﬁgure
2). After inoculation, mice were weekly observed for the
appearance of neurological signs and at the end of their life-
span survival times were determined. The brains were removed
and checked for the presence of PrPres by Western blotting and
IHC. None of the inoculated animals showed any change in
survival times (Table 2) compared to PBS-inoculated control
mice (Table 3). PrPres was not detected neither by Western
blotting nor by IHC indicating the absence of PK resistant
PrP in the inoculated (n = 28) animals (data not shown). These
data demonstrate that bo10ORTg mice do not spontaneously
generate detectable levels of infectious prions in their brains
indicating that the spontaneous disease observed in these mice
is not transmissible at least in a ﬁrst passage. Re-inoculation
studies using brain homogenates from these PrPres negative
animals are currently underway.
3.5. Intracerebral inoculation of bo10ORTg mice with BSE
prions cause BSE
We next investigate the susceptibility of the bo10ORTg mice
to infectious BSE prions. Two diﬀerent inocula (BSE1 and
BSE2) were intracerebrally inoculated (see Section 2 and sup-
plemental ﬁgure 2) in the bo10ORTg012 and bo10ORTg029
mouse lines. The bo10ORTg006 mouse line could not be used
in infectivity studies due to its shorter lifespan (180 ± 10 days),
compared to more than 600 days for the rest of the bo10ORTg
mouse lines used (Table 3).
Recently, we reported that Tg mice expressing bovine PrP
bearing an additional octapeptide insertion with respect to
the wt (7OR instead of 6) showed an altered course of
BSE infection, reﬂected as reduced incubation times when
Table 1
Histopathological studies in non-inoculated bolOORTg mice
Tg line Days after
birth
Neurological
diagnosis ±(n/n0)
b
Lesion
proﬁlec
Cerebellum Brainstem Thalamus Striatum Hippocampus Clinical
signs
bo10ORTg006+/ (4·)a 60 +(4/4) 3 1d 0d 0d 0d 1d 
90 +(5/5) 3 2 0 0 0 1 
120 +(6/6) 3 2–3 0 0 0 1–2 +e
150 +(9/9) 3 2–3 0–1 0 0 2 +e
180 +(16/16) 3 2–3 1–2 0–2 0–2 2 +e
bo10ORTg012+/+ (1·)a 90 (0/6) 0 0 0 0 0 0 
120 (0/4) 0 0 0 0 0 0 
150 (0/6) 0 0 0 0 0 0 
180 (0/6) 0 0 0 0 0 0 
240 (0/8) 0 0 0 0 0 0 
300 +(3/10) 1 1 0–1 0 0 0 
bo10ORTg029+/+ (0.5·)a 120 (0/4) 0 0 0 0 0 0 
180 (0/6) 0 0 0 0 0 0 
240 (0/8) 0 0 0 0 0 0 
300 (0/6) 0 0 0 0 0 0 
400 (0/6) 0 0 0 0 0 0 
+/+ or +/ Homozygotic or heterozygotic for the 10OR bovine prnp gene. All Tg animals are murine prnp/.
aRelative to cattle PrP expression.
bNumber of animals considered as positive for histopathological changes with respect to the total of animals.
cThe lesion proﬁles observed were categorized descriptively as follows: 0, no pathological changes; 1, spongiform change and astrocytosis in
cerebellum (both cortex and white matter), brainstem, striatum and thalamus; 2, changes limited to cerebellum and brainstem; 3, marked changes in
cerebellum, with intense loss of granule cells, and lesser changes in hippocampus.
dThe intensity of pathological changes was graded semi quantitatively as: 0, absent; 1, mild; 2, moderate; 3, severe.
eNeurological signs characterized by motor impairment.
Fig. 4. Insolubility and PK resistance studies of PrPC and PrPres from non-inoculated or BSE-inoculated bo10ORTg and bo6ORTg mouse lines. (A)
Western blot analysis of the soluble (S) and insoluble (P) fractions obtained from non-inoculated bo6ORTg and bo10ORTg brain extracts (10%
Sarkosyl in PBS, pH 7.4 previously pre-cleared by centrifugation at 2000 · g) after ultracentrifugation at 100000 g for 1 h. Insoluble fractions were
washed exhaustively with 5% Sarkosyl in PBS, pH 7.4 and subjected to a further ultracentrifugation step. (B) Western blotting of non-inoculated or
BSE2-inoculated brain homogenates from bo6ORTg110 or bo10ORTg012 mouse lines and cattle were digested with 0, 7.5, 15, 30, 60, 125, 250, 500
and 1000 lg/ml of PK for 60 min at 37 C. An equal volume of 2· SDS sample loading buﬀer was added to all samples and each was boiled for 5 min
before loading onto a SDS/12% polyacrylamide gel. Mab 2A11 was used at a 1/1000 dilution for immunoblotting. Relative molecular mass in
kilodaltons.
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octapeptide protein [17]. To explore if the number of OR inﬂu-
ences the propagation of BSE prions, we also inoculated thesame inocula in mice previously described [27] expressing sim-
ilar or higher levels of the wt six octapeptide protein. When
disease progression was evident the animals were sacriﬁced
Table 3
Susceptibility of bovine 6OR and 10OR Tg mice to BSE prions
Recipient Inoculum Transgene expressiona Death (days ± S.E.M.) n/n0
b
Non-Tg (B6xCBAx129Ola) BSE1 1· (endogenous mouse PrP) 656 ± 30 5/12
Non-Tg (prnp/) BSE1 0· 688 ± 35 0/6
bo6ORTg110+/+d BSE1 8x 326 ± 18 13/13
bo6ORTg110+/d BSE1 4· 359 ± 15 11/11
bo6ORTg113+/+d BSE1 3· 410 ± 7 10/10
bo6ORTg078+/+d BSE1 2· 436 ± 14 10/10
bo6ORTg022+/+d BSE1 0.5· 513 ± 29 9/9
bo10ORTg012+/+ BSE1 1· 276 ± 14 10/10
bo10ORTg029+/+ BSE1 0.5· 320 ± 20 7/7
bo6ORTg110+/+d BSE2 8· 308 ± 5 5/5
bo6ORTg113+/+d BSE2 3· 377 ± 12 7/7
bo10ORTg012+/+ BSE2 1· 261 ± 8 10/10
bo10ORTg029+/+ BSE2 0.5· 260 ± 22 13/13
bo6ORTg110+/+d bol0ORTgBSE1 8· 342 ± 15 11/11
bo10ORTg012+/+ bol0ORTgBSE1 1· 327 ± 15 6/6
bo10ORTg029+/+ bol0ORTgBSE1 0.5· 378 ± 33 5/5
bo6ORTg110+/+d PBS-inoculated 8· >600 0/4
bo6ORTg113+/+d PBS-inoculated 3· 581 ± 39 0/4
bo6ORTg078+/+d PBS-inoculated 2· >500 0/6
bo6ORTg022+/+d PBS-inoculated 0.5· 707 ± 18 0/6
bo10ORTg006+/ PBS-inoculated 4· 180 ± 10c 0/13
bo10ORTg012+/+ PBS-inoculated 1· 685 ± 42 0/9
bo10ORTg029+/+ PBS-inoculated 0.5· >600 0/13
+/+ or +/ Homozygous or heterozygous for the bovine 6OR or 10OR prnp gene. All Tg animals are murine prnp/.
aRelative to cattle PrP expression.
bNumber of animals with PrPres with respect to the number of inoculated animals.
cAnimals were sacriﬁced for ethical reason.
dThese bovine PrP Tg mouse lines have been described previously [17,18,27].
Table 2
Infectivity studies of bovine 10OR Tg mice brain homogenates
Recipient Inoculum Transgene expressiona Death (days ± S.E.M.) n/n0
b
bo6ORTg110+/+c Non-inoculated bo10ORTg006 8· >600 0/6
bo6ORTg135+/+c Non-inoculated bo10ORTg006 6· >600 0/5
bo6ORTg113+/+c Non-inoculated bo10ORTg006 3· 617 ± 78 0/3
bo10ORTg012+/+ Non-inoculated bo10ORTg006 1· 633 ± 33 0/7
bo10ORTg029+/+ Non-inoculated bo10ORTg006 0.5· 632 ± 23 0/7
+/+ or +/ Homozygous or heterozygous for the 6OR or 10OR bovine prnp gene. All Tg animals are murine prnp/.
aRelative to cattle PrP expression.
bNumber of animals with PrPres with respect to the number of inoculated animals.
cThese bovine PrP Tg mouse lines have been described previously [17,18,27].
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studies (Fig. 5B).
In these experiments, the bo10ORTg mice consistently
showed reduced survival times compared to the bo6ORTg
expressing similar or higher levels of the wt PrPC (Table 1). This
reduction in survival times was observed in all the lines express-
ing diﬀerent amounts of bo10ORPrPC and for both the inocula
used. For instance, the bo6ORTg022 mouse line (0.5·) inocu-
lated with BSE1 showed a survival time of 513 ± 29 days, while
this time was 320 ± 20 days for the bo10ORTg029 mouse line,
which expresses identical levels of the 10OR bovine prion pro-
tein (Table 3). Similarly, the bo6ORTg113 (3·) and
bo10ORTg012 (1·) mouse lines inoculated with BSE2 showed
incubation times of 377 ± 12 and 261 ± 8 days, respectively,
although the bo6ORTg113 mouse line expresses 3 times more
bo6OR-PrP than the bo10ORTg012 mouse line (Table 3).3.6. Characterizing the new bo10OR-PrPSc
After intracerebral BSE1 inoculation in bo10ORTg012 and
bo10ORTg029 mouse lines, a new 10OR-PrPSc was obtained.
We named this new prion bo10ORTgBSE1 and then tried to
determine if the four extra octarepeat insert mutation modiﬁes
the biochemical properties and the infectious character of the
new bo10OR-PrPSc protein compared to the wt bo6OR-PrPSc
by assessing insolubility and PK sensitivity as described in Sec-
tion 2. In these studies, the mutant bo10OR-PrP from brains
of spontaneously ill (non-inoculated) bo10ORTg mice was also
assayed. The two PrPSc (bo6OR-PrPSc and bo10OR-PrPSc)
and the bo10OR-PrPC showed similar degree of insolubility
(data not shown). However, while PrPSc from both BSE1 inoc-
ulated bo6ORTg and bo10ORTg mouse lines showed identical
PK resistance, bo10OR-PrPC from non-inoculated bo10ORTg
mouse lines showed reduced PK resistance (Fig. 4B).
Fig. 5. Detection of the PrPres protein in bo6ORTg and bo10ORTg mice after BSE inoculation. (A) Western blot of bo6ORTg brain extracts from
mice intracerebrally inoculated with diﬀerent inocula. (B,C) PrPres immunodetection using mAb 2A11 in the deep layers of the cerebellum (1, 2 and
3), hippocampus (4, 5 and 6) and thalamus (7, 8 and 9) of bo6ORTg (B) or bo10ORTg (C) mice inoculated with BSE2 and bo10ORTgBSE1 inocula
(250 days postinoculation). Monoclonal antibody 2A11 was used at a 1:1500 dilution. Relative molecular mass in kilodaltons.
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ated PrPres by Western blotted detergent extracts of infected
Tg mice brain homogenates after standard proteinase-K treat-
ment. The band patterns for the diﬀerent BSE inocula were
identical for the two diﬀerent passages, regardless of the trans-
gene (data not shown).
In addition, the bo10ORTgBSE1 (bo10OR-PrP
Sc) inoculum
containing similar amounts of PK resistant protein to the
BSE2 inoculum (supplemental ﬁgure 2) was intracerebrally
inoculated in bo10ORTg mouse lines bo10ORTg012 and
bo10ORTg029 and in mice expressing the wt six octapeptide
protein (bo6ORTg110), to compare the course of BSE infec-
tion. In all cases, the new bo10OR-PrPSc was able to infect
100% of the Tg mice independently of the type of bovine
PrP expressed (Table 3), and developed identical signs of
CNS dysfunction after BSE inoculation. Moreover, western
blotting (Fig. 5A) and IHC studies (Fig. 5B) revealed the iden-
tical behavior of the new bo10OR prion used as inoculum.
However, the onset of signs was slightly delayed when these
studies were compared to the standard BSE2 inoculum in the
three diﬀerent lines. Bo10ORTg mice consistently showed re-
duced survival times (Table 3) compared to the bo6ORTg
mouse line. For instance, the bo6ORTg110 mouse line inocu-
lated with BSE2 showed a survival time of 308 ± 5 days, while
this time was 342 ± 15 days when the animals were inoculated
with bo10ORTgBSE1, indicative of a slower propagation. Sim-
ilarly, the bo10ORTg012 and bo10ORTg029 mouse lines inoc-
ulated with BSE2 showed incubation times of 261 ± 8 and
260 ± 22 days, respectively, while these ﬁgures were 327 ± 15
and 378 ± 33 days when bo10ORTgPrPSc was used (Table 3).
In line with the biochemical data, histopathological and
immunohistological studies revealed PrPres deposition in brainsections of mice injected with each of the three types of BSE
inoculum. The histological pattern observed for the BSE inoc-
ulum or ﬁrst passage BSE in bo6ORTg and bo10ORTg mice
(Fig. 5B) was indistinguishable from that of classic BSE in cat-
tle; mainly vacuolization of the neuropil mostly in the brain
stem, hippocampus and cerebellar white matter (Fig. 5B and
C). However, we observed several patterns indicating immu-
nopositivity and correlating Western blot patterns for PrPres.
The most common were ﬁne granular and punctate neuropil
labeling, and stellate labeling foci, which apparently associated
with glial cells. However, we also observed granular staining in
neuronal cytoplasm and around neurons, occasionally as pla-
que-like deposits. These labeling patterns were mostly ob-
served in the neuropil of the rostral brain stem, in cerebellar
nuclei and both in the deep layers of cerebral cortex and in
the hippocampus. This pattern was identical for the bo6ORTg
and bo10ORTg lines, irrespective of the inoculum used
(Fig. 5B and C). Severe vacuolization and PrPres deposition
were accompanied by astrocytic gliosis, as observed by the
immunohistochemical detection of GFAP in diﬀerent struc-
tures of the encephalic area. Vacuoles were often enveloped
by astrocytic prolongations, and astrocytosis was also ob-
served as an enlarged astrocyte cytoplasm. No histopatholo-
gical changes in PrPres deposition (Fig. 5B1, 4 and 7 and
C1, 4 and 7) or in astrocyte reactions (data not shown) were ob-
served in the non-inoculated mice used as negative controls.4. Discussion
Although an infectious origin is the most likely cause of
BSE, other explanations such as a spontaneous/genetic origin,
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have been characterized, mainly in humans, associated with
the presence of an increased number of OR within the PrP
ORF [16,28,29]. Tg mice models over-expressing PrP contain-
ing extra octarepeats conﬁrmed the pathogenicity of this muta-
tion [15,30].
Although bovine PrP with a four extra octarepeat inser-
tional mutation has not yet been naturally found in bovines
it is interesting to assess whether or not this mutation could
potentially manifest as a neurodegenerative syndrome in a bo-
vine PrP context. For this purpose we analyzed the phenotype
of a Tg mouse model expressing a ten octarepeat bovine PrP
gene.
Herein we show that the four extra repeat mutation in the
bovine PrP gene triggers a spontaneous neurodegenerative dis-
ease. Tg mice showed motor impairment with ataxia aﬀecting
mainly the hind limbs but, although clinical signs were visually
manifest, the most important features were the histological
changes in the cerebellum, characterized by atrophy of cerebel-
lar folia with an intense loss of granular cells but preservation
of Purkinje cells. The results also showed that the rate at which
the illness progresses is strongly related to the expression level
of bo10OR-PrPC. These data correlate well with clinical obser-
vations in patients with a four extra repeat mutation in the PrP
gene who are initially aﬀected by progressive cerebellar and
brain stem signs [31]. This neuropathology, with astrogliosis
and massive damage to cerebellar granule cells, is common
in other Tg mice models expressing PrP containing extra oct-
arepeats [15,30] or other point mutations [32]. Most of these
Tg mice models have conﬁrmed that the presence of these
mutations triggers spontaneous disease.
We suggest that the addition of octarepeats generates diﬀer-
ent protein conformations with a varying capacity for patho-
genic conversion and speciﬁc biochemical properties. Hence,
whereas 7OR-PrPC shows similar protease sensitivity and sol-
ubility in non-denaturing detergents to homologous 6OR-PrPC
[17], the addition of four extra octarepeats rendered a
bo10OR-PrPC showing both a reduced protease sensitivity
(Fig. 4B) and a reduced solubility (Fig. 4A) in the same condi-
tions. An increased number of OR has also been related to en-
hanced aggregation and PK resistance of the mutant PrP
protein in hamster [19].
The four extra OR insertion mutation in the PrP could give
rise to a diﬀerent PrP structure with respect to wt PrP. This
conformation, denoted PrPtoxic by other authors [33], show
special biochemical properties, are diﬃcult to degrade and
are prone to build up, triggering a spontaneous disease when
expression levels exceed the clearance threshold. The en-
hanced aggregation and/or protease-resistance properties of
the mutant PrP could in some way aﬀect the appearance of
the disease associated with these mutations. It is clear that
a greater understanding of PrP structure and the eﬀects of
adding octarepeats to its coding region is required. In eﬀect,
it has been proposed that the special properties (toxicity,
insolubility and high aggregation capacity) of PrPs with more
than 7OR could be directly related to their increased number
of OR. The mechanisms through which extra copies of the
OR may inﬂuence the aggregation properties of PrP are un-
clear. However, it has been suggested that the repeat region
of the protein may itself act as a site promoting PrP self-
aggregation or aggregation between PrP and other cell fac-
tors [14,34].On the other hand, Tg mice expressing bovine PrP with ten
octarepeat do not spontaneously generate detectable levels of
infectious prions in their brains (Table 1) indicating that the
spontaneous disease observed in these mice is not transmissi-
ble. While several mutant PrPres like molecules have been gen-
erated in Tg mice and some of these can acquire several
biochemical properties of PrPres, so far none have been shown
to be infectious [14,35] and the transmissibility of these new
pathogenic isoforms is questionable. These data reinforce the
idea that PrP can induce neurodegeneration without being
converted to conventional PrPSc.
Insertional mutation-derived spontaneous human TSEs
show diﬀerent phenotypes and behavior related to the number
of additional OR within the PrP region. Thus, the number of
OR has been shown to aﬀect the severity of symptoms and
the time of onset of clinical signs in humans [29]. Although
it is known that the region comprising the OR is not essential
for mediating the pathogenesis of prions, it does modulate the
incubation time leading to disease [36–38].
In the present study, we also evaluated the eﬀects of the four
extra octarepeats insertion mutation in the bovine PrP on the
eﬃciency of BSE prion propagation. Results showed that BSE
transmission was highly eﬃcient in bo10OR Tg mice, in agree-
ment with the lack of an eﬀective species barrier. In addition,
bo10ORTg mice show an altered course of BSE infection,
resulting in highly reduced survival times when compared to
bo6ORTg mice expressing similar or higher levels of the wt bo-
vine PrP (Fig. 5 and Table 3). Consistent with the lack of a spe-
cies barrier to BSE infection all inoculated mice showed the
typical signs of CNS spongiform degeneration (data not
shown) and PrPres deposits in brain (Fig. 5). The histological
and Western blot patterns observed in both bo6ORTg and
bo10ORTg mice for the diﬀerent BSE inocula used were indis-
tinguishable from those of classic BSE in cattle. These ﬁndings
correlate well with previous observations in Tg mice expressing
bo7OR-PrP [17], in which signiﬁcant diﬀerences in the times of
onset of clinical signs and survival were also reduced after BSE
inoculation.
Despite the BSE agent being considered a slow prion when
propagated in bovine Tg mice requiring models that overex-
press the PrP protein, here we report a bovine PrP Tg mouse
line (bo10ORTg012) with half the normal expression level
(0.5·) and reduced incubation times to disease onset of around
250 days (Table 3). These data suggest that the 10OR-PrP
shows a new conformation that is more eﬃciently converted
into a pathogenic conformation than its 6OR-PrP homologue
(wt). Although, we can not rule out that the new generated
10OR-PrPSc could be more toxic than its homologue 6OR-
PrPSc at equivalent molarity. The existence of seeding mecha-
nisms could explain the fact that low levels of PrP expression
yield reduced incubation times after prion inoculation.
10OR-PrP, a molecule with an evident tendency to aggregate,
could be a good initiator of the conversion–propagation event
triggered by an exogenous prion.
Although the infectivity of the newly formed 10OR-PrPSc
was patent in both bo6ORTg and bo10ORTg inoculated
mice, the survival times of both Tg mice after 10OR-PrPSc
inoculation were slightly longer than the survival times after
6OR-PrPSc inoculation. This once again suggests that the
new pathogenic isoform with 10OR might have a diﬀerent
conformation with respect to the wt isoform bearing 6OR.
These infectivity diﬀerences could be modulated by the initial
6246 J. Castilla et al. / FEBS Letters 579 (2005) 6237–6246PrP conformations, as shown by their diﬀerent biochemical
properties. Our histopathological studies, on the other hand,
revealed the identical behavior of both bovine prions (6OR-
PrPSc and 10OR-PrPSc).
In summary, the addition of OR could give rise to a diﬀerent
PrP structure with respect to wt PrP, capable of acquiring
properties according to the number of OR added. The presence
of four extra OR seems to generate a new 10OR-PrP structure
that can be transformed more eﬃciently than its 6OR-PrP
homologue and has a tendency for aggregation. This ability
could induce a seeding process, or the new conformation could
intrinsically be more susceptible to be transformed into an-
other pathogenic isoform. However, this new conformation
was in no case able to transmit the disease to other mice, even
to homologous 10OR-PrP Tg mice. Thus, if BSE had a genetic
origin, it is unlikely that the causal mutation would be related
to the number of OR.
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